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Abstract 
 
Amitraz,  a  centrally  acting  alpha-2  adrenergic  agonist,  is 
increasingly  being  used  for  treatment  of  ectoparasitic 
infestation  in  cattle.  Its  effects  in  humans  may  mimic 
organophosphate poisoning. We report a case of poisoning 
after suicidal ingestion of Amitraz. The patient presented in 
a  deeply  comatose  state  with  respiratory  depression, 
bradycardia  and  mydriasis  (instead  of  miosis,  the  more 
common presentation in previous reports). He recovered 
completely  within  24  hours  with  adequate  supportive 
measures. The importance of this case report is highlighted 
by the increasing use of this compound, the life-threatening 
presentation, the excellent prognosis with early recognition 
and  supportive  management  and  the  limited  human 
toxicological data. 
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Background 
Amitraz, 1,5 di-(2,4-dimethylphenyl)-3-methyl-1,3,5-tri-aza-
penta-1,4  diene,  is  a  formamidine  pesticide  which  is 
increasingly being used as an insecticide and an acaricide.
1 
Its varied uses include treatment and control of generalised 
demodicosis in canines, ticks and mites on cattle and sheep, 
psylla infection of pears and also for control of red spider 
mites  on  fruit  crop.
1,2  The  formulations  available  for 
commercial use contain 12.5–50% of Amitraz in an organic 
solvent like xylene and is diluted with water before use.
3.4 
Amitraz  is  an  uncommon  poisoning  in  humans  and  may 
occur  via  oral,  dermal  or  inhalational  routes.  Being  a 
centrally acting alpha-2  adrenergic agonist, it can present 
with  life-threatening  effects  such  as  varying  degrees  of 
central  nervous  system  (CNS)  depression,  hypotension, 
bradycardia,  hypothermia  and  respiratory  depression.  We 
would  like  to  emphasise  that  although  Amitraz  poisoning 
has  a  life-threatening  presentation,  most  cases  result  in 
complete  recovery  if  appropriate  supportive  treatment  is 
instituted  in  a  timely  fashion.  A  limited  number  of  case 
reports of human intoxication have been published, many 
of which are from Turkey. Most of these cases are those of 
accidental  intake  in  children.  This  is  thought  to  be  the 
second case report from India to date.  Thus, it significantly 
contributes to the limited pool of data available about this 
poison, thereby allowing timely recognition and treatment. 
 
Case details 
An 18-year-old male patient, was brought to our emergency 
department (ED) with a history of consumption of 50ml of 
Amitraz poison six hours before being brought to our ED. He 
had consumed the poison after a quarrel with his father. 
Subsequently, he vomited and informed his parents, thus he 
was  taken  to  a  hospital  in  their  locality.  He  was  given  a 
gastric  lavage  and  intravenous  crystalloids  were  started. 
Over the next couple of hours, his sensorium deteriorated. 
There was no history suggestive of seizures. The patient did 
not have any known premorbid medical condition and had 
no history of prescription drug usage.  He was referred to 
our hospital for further management.  
 
On  arrival  at  our  ED,  he  was  deeply  comatose  with  a 
Glasgow Coma Scale (GCS) of 4/15. His heart rate was 52 
beats per minute and blood pressure was 96/68mm Hg. He 
had a shallow respiration with a respiratory rate of 16/min. 
Oxygen  saturation  at  presentation  was  75%  on  room  air, 
which improved to 99% with oxygen delivered  via a 60% 
venturi face mask at a flow of 15L/min. On examination of 
the CNS, his pupils were bilaterally dilated (5mm) and not 
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reacting to light, all four limbs had hypotonia and there was 
bilateral  flexor  plantar  response.  Bowel  sounds  were 
sluggish. Other systemic examinations were normal. There 
were  no  excessive  oral  secretions  or  any  fasciculations. 
Baseline  line  blood  investigations  (complete  blood  count, 
renal function test, serum electrolytes, liver function test), 
plasma  butyrylcholinesterase  level,  electrocardiogram, 
chest X-ray, routine urine testing were normal. A urine test 
for drugs of abuse was negative. Blood alcohol level was 
normal.  The patient was given supportive treatment in our 
intensive care unit in the form of intravenous fluids, proton 
pump  inhibitors  and  oxygen  by  venturi  mask.  Vital  signs 
were  constantly  monitored.  Urine  output  was  adequate.  
Over  the  next  24  hours,  he  gradually  regained  complete 
consciousness.  His  heart  rate  was  78  beats  per  minute, 
blood  pressure  was  124/84  mm  Hg  and  he  maintained 
normal  oxygen  saturation  under  room  air.  Neurological 
examination was normal. Bowel sounds returned to normal. 
He  was  transferred  to  the  general  ward  and  was 
subsequently  discharged  after  consulting  the  psychiatrist 
and a clinical psychologist. 
 
Discussion 
Amitraz is increasingly being used worldwide in veterinary 
medicine and agriculture. It can cause poisoning in animals 
and  humans  via  oral,  dermal  or  inhalation  routes.  The 
toxicity  from  this  poisoning  can  be  attributed  to  both 
Amitraz and the solvent, xylene. Although the ingested dose 
of Amitraz cannot be determined because it is diluted at 1 
part in 500 before usage, the acute oral median lethal dose 
(LD50) for rats is 800mg/kg body weight.
1,2 Amitraz is a α2 
adrenergic  agonist  and  the  effects  resemble  that  of 
Clonidine.
 6 It stimulates α2 receptors in the CNS and α2 and 
α1 receptors in the periphery.
7 The clinical manifestations 
due  to  this  pharmacodynamic  property  include  CNS 
depression  (drowsiness,  coma,  convulsion),  respiratory 
depression, hypotension, bradycardia, hypothermia, miosis 
(presynaptic  effect  at  low  doses)  or  rarely  mydriasis 
(postsynaptic effect at higher doses), polyuria (inhibition of 
antidiuretic hormone and renin)
2 and intestinal distension. 
Our patient had deterioration of sensorium progressing to 
deep  coma  within  approximately  150  minutes  after 
consumption  of  the  poison.  CNS  depression  developing 
within  30  to  180  minutes  was  seen  as  one  of  the  most 
common manifestation in other studies.
1,2,5,8 Seizures have 
been  reported  by  Yilmaz  et  al  and  Ertekin  et  al  and 
responded  to  treatment  with  injectable  diazepam  or 
lorazepam.  The  solvent,  xylene,  may  additionally  cause 
acute  toxic  signs  like  CNS  depression,  ataxia,  nystagmus, 
stupor, coma and episodes of neuroirritability.
1  Although 
our  patient  had  mild  respiratory  depression  and 
bradycardia, he improved with oxygen supplementation and 
did  not  require  atropine  for  the  bradycardia.  Significant 
respiratory  depression  and  bradycardia  requiring 
mechanical ventilation and atropine respectively have been 
reported in previous studies.
1,8 Unlike most of the earlier 
studies  where  miosis  was  predominant,  our  patient 
presented with mydriasis which has rarely been seen after 
consumption of Amitraz in some studies.
2,9 Our patient did 
not  have  polyuria  as  seen  occasionally  in  some  study 
groups.
2 Amitraz can also inhibit prostaglandin E2 synthesis 
and thus contribute to the hypothermia caused by central 
α2 adrenergic agonist action.
1 
 
The  laboratory  investigations  of  our  patient  were  normal 
except decreased oxygen saturation on arterial blood gas 
analysis which was also noted by Yilmaz et al. Amitraz is a 
potent hepatotoxic drug which acts by decreasing hepatic 
glutathione activity but the liver enzymes have been shown 
to return to baseline within 48 hours.
5 It is a potent inhibitor 
of liver monoamine oxidase enzyme in rats.
1 Hyperglycemia 
and glycosuria has been seen in some studies.  α2 adrenergic 
stimulation reduces insulin secretion and increases glucagon 
secretion as demonstrated in perfused rat pancreas by Abu-
Basha et al.
10 Kalyoncu et al reported hyponatremia in three 
cases.
11  Our  patient  did  not  have  any  of  the  above 
metabolic abnormalities. 
 
If  the  patient  presents  with  bradycardia  and  miosis, 
organophosphate  poisoning  should  be  considered  as  a 
possible differential diagnosis. Other symptoms and signs of 
organophosphate  poisoning  should  be  looked  for  and  a 
plasma butyrylcholinesterase level should be estimated in 
such cases. Amitraz level in the blood was not done because 
it  was  unavailable  at  our  institute  and  our  referral 
laboratories. 
 
There  is  no  antidote  available  for  Amitraz  poisoning. 
Management  involves  supportive  measures  like  gastric 
lavage  (though  Yilmaz  et  al  advises  against  it,  unless  the 
patient is first intubated because of chances of aspiration 
pneumonia  due  to  petroleum  distillates  in  Amitraz 
formulations),  activated  charcoal  administration,  and 
securing the airway. Additional measures depending on the 
patient’s  condition  can  be  instituted  like  oxygen 
supplementation or mechanical ventilation for respiratory 
depression,  atropine  for  severe  bradycardia,  intravenous 
fluids  and  vasopressors  for  hypotension,  diazepam  or 
lorazepam for seizures. In most studies, the CNS depression 
recovered within 4–28 hours like in our patient. Most cases 
completely  recover  with  aggressive  supportive  treatment.  Australasian Medical Journal [AMJ 2011, 4, 8, 439-441] 
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Only  two  cases  of  death  due  to  this  drug  have  been 
reported in the literature.
 2 
 
Through this report, we wish to contribute to the limited 
human toxicological data on Amitraz. With the increasing 
usage of Amitraz in veterinary medicine and agriculture, the 
emerging  problem  of  this  unusual  poisoning  is  bound  to 
increase.  We would like to emphasise that though Amitraz 
poisoning  may  have  a  life-threatening  presentation,  early 
initiation of aggressive supportive management is the key to 
a favourable outcome.  
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